Literature DB >> 22056282

Association of cord blood magnesium concentration and neonatal resuscitation.

Lynn H Johnson1, Delicia C Mapp, Dwight J Rouse, Catherine Y Spong, Brian M Mercer, Kenneth J Leveno, Michael W Varner, Jay D Iams, Yoram Sorokin, Susan M Ramin, Menachem Miodovnik, Mary J O'Sullivan, Alan M Peaceman, Steve N Caritis.   

Abstract

OBJECTIVE: To assess the relationship between umbilical cord blood magnesium concentration and level of delivery room resuscitation received by neonates. STUDY
DESIGN: This was a secondary analysis of a controlled fetal neuroprotection trial that enrolled women at imminent risk for delivery between 24 and 31 weeks' gestation and randomly allocated them to receive either intravenous magnesium sulfate or placebo. The cohort included 1507 infants with data available on total cord blood Mg concentration and delivery room resuscitation. Multivariate logistic regression was used to estimate the association between cord blood Mg concentration and highest level of delivery room resuscitation, using the following hierarchy: none, oxygen only, bag-mask ventilation with oxygen, intubation, and chest compressions.
RESULTS: There was no relationship between cord blood Mg and delivery room resuscitation (OR, 0.92 for each 1.0-mEq/L increase in Mg; 95% CI, 0.83-1.03). Maternal general anesthesia was associated with increased neonatal resuscitation (OR, 2.51; 95% CI, 1.72-3.68). Each 1-week increase in gestational age at birth was associated with decreased neonatal resuscitation (OR, 0.63; 95% CI, 0.60-0.66).
CONCLUSION: Cord blood Mg concentration does not correlate with the level of delivery room resuscitation of infants exposed to magnesium sulfate for fetal neuroprotection. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056282      PMCID: PMC3998513          DOI: 10.1016/j.jpeds.2011.09.016

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  Ante- and intra-partum factors that predict increased need for neonatal resuscitation.

Authors:  Khalid Aziz; Mairi Chadwick; Mary Baker; Wayne Andrews
Journal:  Resuscitation       Date:  2008-10-25       Impact factor: 5.262

Review 2.  Magnesium sulfate and cerebral palsy in premature infants.

Authors:  D G Hirtz; K Nelson
Journal:  Curr Opin Pediatr       Date:  1998-04       Impact factor: 2.856

3.  Influence of maternal magnesium sulphate and ritodrine treatment on the neonate: a study with six-month follow-up.

Authors:  T Rantonen; U Ekblad; J Grönlund; H Rikalainen; I Välimäki; P Kero
Journal:  Acta Paediatr       Date:  1999-10       Impact factor: 2.299

4.  Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*.

Authors:  S Marret; L Marpeau; V Zupan-Simunek; D Eurin; C Lévêque; M-F Hellot; J Bénichou
Journal:  BJOG       Date:  2006-12-04       Impact factor: 6.531

5.  Neurobehavioral effects of neonatal hypermagnesemia.

Authors:  D K Rasch; P A Huber; C J Richardson; C S L'Hommedieu; T E Nelson; R Reddi
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

6.  The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study.

Authors:  M Riaz; R Porat; N L Brodsky; H Hurt
Journal:  J Perinatol       Date:  1998 Nov-Dec       Impact factor: 2.521

Review 7.  Magnesium sulfate for preterm labor and preterm birth.

Authors:  Brian M Mercer; Amy A Merlino
Journal:  Obstet Gynecol       Date:  2009-09       Impact factor: 7.661

8.  Predictors of neonatal resuscitation, low Apgar scores, and umbilical artery pH among growth-restricted neonates.

Authors:  B T Levy; J D Dawson; P P Toth; N Bowdler
Journal:  Obstet Gynecol       Date:  1998-06       Impact factor: 7.661

9.  Neonatal asphyxia. I. Relationship of obstetric and neonatal complications to neonatal mortality in 38,405 consecutive deliveries.

Authors:  H M MacDonald; J C Mulligan; A C Allen; P M Taylor
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

10.  A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.

Authors:  Dwight J Rouse; Deborah G Hirtz; Elizabeth Thom; Michael W Varner; Catherine Y Spong; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; James M Alexander; Margaret Harper; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall Carpenter; Menachem Miodovnik; Atef Moawad; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Oded Langer; Steve N Caritis; James M Roberts
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

View more
  10 in total

1.  Delivery Room Resuscitation and Short-Term Outcomes in Moderately Preterm Infants.

Authors:  Monika Bajaj; Girija Natarajan; Seetha Shankaran; Myra Wyckoff; Abbot R Laptook; Edward F Bell; Barbara J Stoll; Waldemar A Carlo; Betty R Vohr; Shampa Saha; Krisa P Van Meurs; Pablo J Sanchez; Carl T D'Angio; Rosemary D Higgins; Abhik Das; Nancy Newman; Michele C Walsh
Journal:  J Pediatr       Date:  2018-01-03       Impact factor: 4.406

Review 2.  Antenatal prevention of cerebral palsy and childhood disability: is the impossible possible?

Authors:  Stacey J Ellery; Meredith Kelleher; Peta Grigsby; Irina Burd; Jan B Derks; Jon Hirst; Suzanne L Miller; Larry S Sherman; Mary Tolcos; David W Walker
Journal:  J Physiol       Date:  2018-07-21       Impact factor: 5.182

3.  Effect of dexamethasone administered with magnesium sulfate on inflammation-mediated degradation of the blood-brain barrier using an in vitro model.

Authors:  Monica A Lutgendorf; Danielle L Ippolito; Mariano T Mesngon; Deborah Tinnemore; Mary Jo Dehart; Brad M Dolinsky; Peter G Napolitano
Journal:  Reprod Sci       Date:  2013-09-27       Impact factor: 3.060

4.  Magnesium sulfate exposure and neonatal intensive care unit admission at term.

Authors:  A I Girsen; M B Greenberg; Y Y El-Sayed; H Lee; B Carvalho; D J Lyell
Journal:  J Perinatol       Date:  2014-10-16       Impact factor: 2.521

Review 5.  Perinatal management: What has been learned through the network?

Authors:  Sanjay Chawla; Elizabeth E Foglia; Vishal Kapadia; Myra H Wyckoff
Journal:  Semin Perinatol       Date:  2016-08-01       Impact factor: 3.300

6.  Antenatal magnesium sulfate exposure and acute cardiorespiratory events in preterm infants.

Authors:  Lilia C De Jesus; Beena G Sood; Seetha Shankaran; Douglas Kendrick; Abhik Das; Edward F Bell; Barbara J Stoll; Abbot R Laptook; Michele C Walsh; Waldemar A Carlo; Pablo J Sanchez; Krisa P Van Meurs; Rebecca Bara; Ellen C Hale; Nancy S Newman; M Bethany Ball; Rosemary D Higgins
Journal:  Am J Obstet Gynecol       Date:  2014-07-18       Impact factor: 8.661

7.  Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis.

Authors:  Celeste D Bickford; Laura A Magee; Craig Mitton; Marie Kruse; Anne R Synnes; Diane Sawchuck; Melanie Basso; Vyta M Senikas; Peter von Dadelszen
Journal:  BMC Health Serv Res       Date:  2013-12-19       Impact factor: 2.655

8.  MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada.

Authors:  Dane A De Silva; Anne R Synnes; Peter von Dadelszen; Tang Lee; Jeffrey N Bone; Laura A Magee
Journal:  Implement Sci       Date:  2018-01-11       Impact factor: 7.327

9.  Cord Blood Haptoglobin, Cerebral Palsy and Death in Infants of Women at Risk for Preterm Birth: A Secondary Analysis of a Randomised Controlled Trial.

Authors:  Catalin S Buhimschi; Kathleen A Jablonski; Dwight J Rouse; Michael W Varner; Uma M Reddy; Brian M Mercer; Kenneth J Leveno; Ronald J Wapner; Yoram Sorokin; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall W Carpenter; Mary J O'Sullivan; Alan M Peaceman; George R Saade; Donald Dudley; Steve N Caritis; Irina A Buhimschi
Journal:  EClinicalMedicine       Date:  2019-03-22

Review 10.  Effects and Safety of Magnesium Sulfate on Neuroprotection: A Meta-analysis Based on PRISMA Guidelines.

Authors:  Xianling Zeng; Yan Xue; Quan Tian; Rong Sun; Ruifang An
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.